Fielding James E, Levy Avram, Chilver Monique B, Deng Yi-Mo, Regan Annette K, Grant Kristina A, Stocks Nigel P, Sullivan Sheena G
Victorian Infectious Diseases Reference Laboratory, The Doherty Institute, Melbourne, Victoria, Australia; National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
PathWest Laboratory Medicine WA, Perth, Western Australia, Australia; School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia.
Vaccine. 2016 Sep 22;34(41):4905-4912. doi: 10.1016/j.vaccine.2016.08.067. Epub 2016 Aug 28.
A record number of laboratory-confirmed influenza cases were notified in Australia in 2015, during which type A(H3) and type B Victoria and Yamagata lineages co-circulated. We estimated effectiveness of the 2015 inactivated seasonal influenza vaccine against specific virus lineages and clades.
Three sentinel general practitioner networks conduct surveillance for laboratory-confirmed influenza amongst patients presenting with influenza-like illness in Australia. Data from the networks were pooled to estimate vaccine effectiveness (VE) for seasonal trivalent influenza vaccine in Australia in 2015 using the case test-negative study design.
There were 2443 eligible patients included in the study, of which 857 (35%) were influenza-positive. Thirty-three and 19% of controls and cases respectively were reported as vaccinated. Adjusted VE against all influenza was 54% (95% CI: 42, 63). Antigenic characterisation data suggested good match between vaccine and circulating strains of A(H3); however VE for A(H3) was low at 44% (95% CI: 21, 60). Phylogenetic analysis indicated most circulating viruses were from clade 3C.2a, rather than the clade included in the vaccine (3C.3a). VE point estimates were higher against B/Yamagata lineage influenza (71%; 95% CI: 57, 80) than B/Victoria (42%, 95% CI: 13, 61), and in younger people.
Overall seasonal vaccine was protective against influenza infection in Australia in 2015. Higher VE against the B/Yamagata lineage included in the trivalent vaccine suggests that more widespread use of quadrivalent vaccine could have improved overall effectiveness of influenza vaccine. Genetic characterisation suggested lower VE against A(H3) influenza was due to clade mismatch of vaccine and circulating viruses.
2015年澳大利亚报告的实验室确诊流感病例数量创历史新高,期间甲型(H3)流感病毒以及乙型维多利亚系和山形系病毒共同传播。我们评估了2015年季节性流感灭活疫苗针对特定病毒系和进化枝的有效性。
澳大利亚的三个哨点全科医生网络对出现流感样疾病的患者进行实验室确诊流感监测。汇总这些网络的数据,采用病例检测阴性研究设计估算2015年澳大利亚季节性三价流感疫苗的疫苗效力(VE)。
该研究共纳入2443例符合条件的患者,其中857例(35%)流感检测呈阳性。分别有33%的对照者和19%的病例报告接种过疫苗。针对所有流感病毒的校正疫苗效力为54%(95%置信区间:42, 63)。抗原特性分析数据表明疫苗与A(H3)流感病毒的流行毒株匹配良好;然而,A(H3)流感病毒的疫苗效力较低,为44%(95%置信区间:21, 60)。系统发育分析表明,大多数流行病毒来自3C.2a进化枝,而非疫苗中包含的进化枝(3C.3a)。针对乙型山形系流感病毒的疫苗效力点估计值(71%;95%置信区间:57, 80)高于乙型维多利亚系(42%,95%置信区间:13, 61),且在年轻人中更高。
2015年澳大利亚的整体季节性疫苗对流感感染具有保护作用。针对三价疫苗中包含的乙型山形系流感病毒的较高疫苗效力表明,更广泛地使用四价疫苗可能会提高流感疫苗的整体效力。基因特性分析表明,针对甲型(H3)流感病毒的较低疫苗效力是由于疫苗与流行病毒的进化枝不匹配。